Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.
Gilead Sciences (GILD) closed at $72.31 in the latest trading session, marking a +1.54% move from the prior day. This change outpaced the S&P 500's 0.87% loss on the day. Meanwhile, the Dow lost 0.08%, and the Nasdaq, a tech-heavy index, lost 0.54%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 5.56% over the past month. This has outpaced the Medical sector's loss of 0.67% and the S&P 500's gain of 0.7% in that time.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release. On that day, Gilead Sciences is projected to report earnings of $1.45 per share, which would represent a year-over-year decline of 33.79%. Our most recent consensus estimate is calling for quarterly revenue of $6.39 billion, down 13.89% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $8.07 per share and revenue of $26.48 billion. These totals would mark changes of +13.82% and +7.24%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.14% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 8.82. This valuation marks a discount compared to its industry's average Forward P/E of 22.45.
Also, we should mention that GILD has a PEG ratio of 0.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.58 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research